Excelsyn Ltd @ InformEx USA 2010, stand 1334

Published: 10-Feb-2010

Excelsyn is an experienced chemistry services provider to the biotechnology and pharmaceutical industries. We offer a broad range of cost-effective integrated services to support drug candidate development from optimised lead through to commercial production, including synthetic route evaluation, process development, scale-up and production from grams to tonnes.
The success of Excelsyn and the strong customer relationships is demonstrated by:
A global reach to customers in Europe and US
A repeat business rate of 75%
An enquiry to deal rate of 35% for new opportunities
The key to our success is achieved by:
Problem solving
Flexibility
Speed
Cost focus
  • Companies:
  • Informa
See more

You may also like

Marketing

CPHI Pharma Awards 2025 winners announced

Read more
Hundreds of entries received across 13 categories showcasing industry-wide excellence

Trending Articles

  1. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research
  2. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  3. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  4. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
  5. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027

You may also like

Marketing

CPHI Pharma Awards 2025 winners announced

Hundreds of entries received across 13 categories showcasing industry-wide excellence
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Manufacturing

CPHI & PMEC China sees surge in international attendance as globalpharma trade outlook strengthens

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing,as easing tariffs fuel growth
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Of data, devices and drug delivery

Ahead of Pharmapack Europe 2025 (22–23January, Paris, France), Dr Kevin Robinson (KSR) spoke with three pharma leaders about the big trends that will drive and influence the pharmaceutical sector in 2025
Manufacturing

Faster CDMO growth in 2025 predicted and industry not in favour of BIOSECURE Act, states CPHI Milan survey

CPHI Milan returns next month at a pivotal moment as contract services growth is predicted to accelerate in 2025
Pharmaceutical

CPHI Milan announces the finalists for 14 categories of the Pharma Awards

Awards for future leaders, women of the year and those at the heart of pharma will be handed out at the CPHI Pharma Awards ceremony
Ingredients

CPHI Milan Annual Report 2024

Ahead of next month’s CPHI Milan — where the industry is expected to turnout in record numbers with a staggering 62,000 pharma executives expected from more than 100 countries — Manufacturing Chemist got a sneak preview of the CPHI Annual Reports Excipients Analysis featuring Ian Moore’s (former Chair of the IPEC Europe GMP Committee) personal predictions for the year ahead
Subscribe now